Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second IVIg Dose in Guillain-Barré Syndrome With Poor Prognosis
NL-OMON35287Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of immune globulin in Guillain-Barré syndrome (GBS) and acute inflammatory demyelinating polyneuropathy (AIDP) (2 arms), sponsored by Erasmus MC. Primary endpoint: GBS disability score at 4 weeks. Started Nov 2011; status: active, not recruiting.
02
Drugs
immune globulin
03
Conditions
Guillain-Barré syndrome (GBS)acute inflammatory demyelinating polyneuropathy (AIDP)
Beyond the preview
Go deeper on NL-OMON35287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35287.